Weil advised Biogroup on the amendment and extension of its existing facilities agreement, including the upsize and maturity extension of its term loan facilities in an aggregate principal amount equal to €1,400 million, as well as the establishment of a new €280 million revolving facility.

Weil also advised Biogroup in connection with its successful issuance of €1,300 million senior secured notes due 2031 and the concurrent exchange offers and consent solicitations launched by Biogroup on its outstanding senior secured notes due 2028 and senior notes 2029.

This landmark transaction represents one of the largest refinancing operations in the European healthcare sector in recent years. Proceeds of the notes will be used to refinance part of Biogroup’s existing term loan facilities and its outstanding senior secured notes due 2028 not otherwise exchanged in the exchange offers.

Biogroup is a leading European provider of medical diagnostics services, delivering routine and specialized laboratory testing as well as diagnostic imaging through an extensive network of collection sites across France, Belgium, Luxembourg and Iberia.

The Weil team was led by Finance partner Jean-Christophe David and High Yield partner Gilles Teerlinck, and included Finance associates Marc-Aurèle Berret and Axel Cadet in Paris and High Yield associate Roberto Storlazzi in London.